ABFM + KSA DIABETES CERTIFICATION EXAM– QUESTIONS AND ANSWERS | VERIFIED AND WELL
DETAILED ANSWERS | PLUS RATIONALES | DOWNLOAD AND PASS | LATEST EXAM UPDATE 2026/2027]
– QUESTIONS AND ANSWERS | VERIFIED AND WELL DETAILED ANSWERS | PLUS RATIONALES |
GUARANTEED PASS | LATEST EXAM UPDATE
CORE DOMAINS
1. Diabetes Pathophysiology and Classification
2. Diagnostic Criteria and Glycemic Targets
3. Pharmacologic Management of Type 2 Diabetes
4. Insulin Therapy and Intensive Management
5. Diabetes Complications: Microvascular and Macrovascular
6. Acute Complications of Diabetes
7. Special Populations in Diabetes Care
8. Lifestyle, Nutrition, and Self-Management Education
9. Monitoring Technologies and Interpretation
10. Regulatory, Ethical, and Professional Standards in Diabetes Care
INTRODUCTION
This comprehensive certification assessment is designed to evaluate the knowledge, clinical reasoning,
and professional judgment required for excellence in diabetes care. It assesses foundational theory,
applied clinical knowledge, technical concepts, regulatory compliance, ethical standards, and real-
world decision-making. The examination employs multiple-choice and scenario-based questions that
reflect the complexities of contemporary diabetes management. Emphasis is placed on practical
application, interpretation of clinical data, safety, and professional responsibility. This assessment
serves as a rigorous tool for certification preparation and continuous professional development in
diabetes care.
SECTION ONE – QUESTIONS 1–100
Question 1
A 52-year-old patient presents with polyuria, polydipsia, and a random plasma glucose of 245 mg/dL.
Which diagnostic criterion confirms diabetes mellitus?
A. Fasting plasma glucose ≥126 mg/dL
B. Random plasma glucose ≥200 mg/dL with classic symptoms
C. HbA1c ≥5.7%
D. Two-hour plasma glucose ≥140 mg/dL during OGTT
🟢 B. Random plasma glucose ≥200 mg/dL with classic symptoms
🔴 Explanation: A random plasma glucose ≥200 mg/dL accompanied by classic symptoms of
hyperglycemia (polyuria, polydipsia, polyphagia) is diagnostic of diabetes mellitus without requiring a
second confirmatory test.
,Question 2
Which pathophysiologic defect is most characteristic of type 2 diabetes mellitus?
A. Absolute insulin deficiency due to autoimmune beta-cell destruction
B. Insulin resistance with progressive beta-cell dysfunction
C. Glucagon excess without insulin deficiency
D. Defective proinsulin conversion
🟢 B. Insulin resistance with progressive beta-cell dysfunction
🔴 Explanation: Type 2 diabetes is characterized by peripheral insulin resistance and a progressive
decline in beta-cell function, leading to relative insulin deficiency.
Question 3
A 45-year-old patient with BMI 34 kg/m² and fasting glucose of 118 mg/dL should be classified as
having:
A. Normal glucose tolerance
B. Prediabetes
C. Type 1 diabetes
D. Type 2 diabetes
🟢 B. Prediabetes
🔴 Explanation: Fasting plasma glucose between 100–125 mg/dL defines impaired fasting glucose, a
category of prediabetes.
Question 4
Which autoantibody is most commonly associated with type 1 diabetes mellitus?
A. Anti-nuclear antibody
B. Anti-glutamic acid decarboxylase (GAD65)
C. Rheumatoid factor
D. Anti-thyroid peroxidase
🟢 B. Anti-glutamic acid decarboxylase (GAD65)
🔴 Explanation: GAD65 autoantibodies are present in approximately 70–80% of patients with new-
onset type 1 diabetes and are the most sensitive marker.
Question 5
A patient with type 1 diabetes presents with fasting hyperglycemia despite adequate basal insulin.
Which phenomenon should be suspected?
A. Somogyi effect
B. Dawn phenomenon
C. Insulin resistance
D. Gastroparesis
🟢 B. Dawn phenomenon
🔴 Explanation: The dawn phenomenon is caused by nocturnal release of counterregulatory hormones
(growth hormone, cortisol) leading to early morning hyperglycemia despite adequate insulin.
Question 6
Which HbA1c target is generally recommended for most non-pregnant adults with diabetes?
,A. <6.0%
B. <6.5%
C. <7.0%
D. <8.0%
🟢 C. <7.0%
🔴 Explanation: The American Diabetes Association recommends an HbA1c target of <7.0% for most
non-pregnant adults to reduce microvascular complications.
Question 7
A 58-year-old patient with type 2 diabetes has an eGFR of 35 mL/min/1.73m². Which oral agent should
be avoided?
A. Sitagliptin
B. Metformin
C. Linagliptin
D. Empagliflozin
🟢 B. Metformin
🔴 Explanation: Metformin is contraindicated when eGFR is below 30 mL/min/1.73m² and should be
used with caution at eGFR 30–45 due to risk of lactic acidosis.
Question 8
Which class of antihyperglycemic agents works by inhibiting renal sodium-glucose cotransporter 2?
A. DPP-4 inhibitors
B. GLP-1 receptor agonists
C. SGLT2 inhibitors
D. Thiazolidinediones
🟢 C. SGLT2 inhibitors
🔴 Explanation: SGLT2 inhibitors block glucose reabsorption in the proximal renal tubule, promoting
glycosuria and lowering blood glucose independently of insulin.
Question 9
A patient on insulin reports hypoglycemia at 3:00 AM with rebound hyperglycemia at 7:00 AM. This is
most consistent with:
A. Dawn phenomenon
B. Somogyi effect
C. Insulin stacking
D. Gastroparesis
🟢 B. Somogyi effect
🔴 Explanation: The Somogyi effect involves nocturnal hypoglycemia triggering counterregulatory
hormone release, resulting in rebound morning hyperglycemia.
Question 10
Which of the following is the preferred initial injectable therapy for a patient with type 2 diabetes and
established cardiovascular disease?
A. NPH insulin
, B. GLP-1 receptor agonist
C. Premixed insulin
D. Regular insulin
🟢 B. GLP-1 receptor agonist
🔴 Explanation: GLP-1 receptor agonists with proven cardiovascular benefit are recommended as
preferred injectable therapy in patients with type 2 diabetes and atherosclerotic cardiovascular disease.
Question 11
A 62-year-old man with type 2 diabetes has an HbA1c of 9.2% on metformin monotherapy. What is
the most appropriate next step?
A. Add a sulfonylurea
B. Add a second oral agent or injectable therapy
C. Continue metformin alone
D. Discontinue metformin and start insulin
🟢 B. Add a second oral agent or injectable therapy
🔴 Explanation: When HbA1c is >1.5% above target on monotherapy, combination therapy with a
second agent is indicated.
Question 12
Which of the following is a common adverse effect of metformin?
A. Weight gain
B. Hypoglycemia
C. Gastrointestinal upset
D. Peripheral edema
🟢 C. Gastrointestinal upset
🔴 Explanation: Metformin commonly causes gastrointestinal side effects including diarrhea, nausea,
and abdominal discomfort.
Question 13
Diabetic ketoacidosis is characterized by all of the following EXCEPT:
A. Hyperglycemia
B. Metabolic acidosis
C. Ketosis
D. Respiratory alkalosis
🟢 D. Respiratory alkalosis
🔴 Explanation: DKA presents with metabolic acidosis, not respiratory alkalosis. Compensatory
respiratory alkalosis may occur but is not a defining feature.
Question 14
A patient with DKA has a pH of 7.12, bicarbonate of 8 mEq/L, and glucose of 480 mg/dL. What is the
initial priority?
A. Insulin bolus
B. IV fluid resuscitation with normal saline
DETAILED ANSWERS | PLUS RATIONALES | DOWNLOAD AND PASS | LATEST EXAM UPDATE 2026/2027]
– QUESTIONS AND ANSWERS | VERIFIED AND WELL DETAILED ANSWERS | PLUS RATIONALES |
GUARANTEED PASS | LATEST EXAM UPDATE
CORE DOMAINS
1. Diabetes Pathophysiology and Classification
2. Diagnostic Criteria and Glycemic Targets
3. Pharmacologic Management of Type 2 Diabetes
4. Insulin Therapy and Intensive Management
5. Diabetes Complications: Microvascular and Macrovascular
6. Acute Complications of Diabetes
7. Special Populations in Diabetes Care
8. Lifestyle, Nutrition, and Self-Management Education
9. Monitoring Technologies and Interpretation
10. Regulatory, Ethical, and Professional Standards in Diabetes Care
INTRODUCTION
This comprehensive certification assessment is designed to evaluate the knowledge, clinical reasoning,
and professional judgment required for excellence in diabetes care. It assesses foundational theory,
applied clinical knowledge, technical concepts, regulatory compliance, ethical standards, and real-
world decision-making. The examination employs multiple-choice and scenario-based questions that
reflect the complexities of contemporary diabetes management. Emphasis is placed on practical
application, interpretation of clinical data, safety, and professional responsibility. This assessment
serves as a rigorous tool for certification preparation and continuous professional development in
diabetes care.
SECTION ONE – QUESTIONS 1–100
Question 1
A 52-year-old patient presents with polyuria, polydipsia, and a random plasma glucose of 245 mg/dL.
Which diagnostic criterion confirms diabetes mellitus?
A. Fasting plasma glucose ≥126 mg/dL
B. Random plasma glucose ≥200 mg/dL with classic symptoms
C. HbA1c ≥5.7%
D. Two-hour plasma glucose ≥140 mg/dL during OGTT
🟢 B. Random plasma glucose ≥200 mg/dL with classic symptoms
🔴 Explanation: A random plasma glucose ≥200 mg/dL accompanied by classic symptoms of
hyperglycemia (polyuria, polydipsia, polyphagia) is diagnostic of diabetes mellitus without requiring a
second confirmatory test.
,Question 2
Which pathophysiologic defect is most characteristic of type 2 diabetes mellitus?
A. Absolute insulin deficiency due to autoimmune beta-cell destruction
B. Insulin resistance with progressive beta-cell dysfunction
C. Glucagon excess without insulin deficiency
D. Defective proinsulin conversion
🟢 B. Insulin resistance with progressive beta-cell dysfunction
🔴 Explanation: Type 2 diabetes is characterized by peripheral insulin resistance and a progressive
decline in beta-cell function, leading to relative insulin deficiency.
Question 3
A 45-year-old patient with BMI 34 kg/m² and fasting glucose of 118 mg/dL should be classified as
having:
A. Normal glucose tolerance
B. Prediabetes
C. Type 1 diabetes
D. Type 2 diabetes
🟢 B. Prediabetes
🔴 Explanation: Fasting plasma glucose between 100–125 mg/dL defines impaired fasting glucose, a
category of prediabetes.
Question 4
Which autoantibody is most commonly associated with type 1 diabetes mellitus?
A. Anti-nuclear antibody
B. Anti-glutamic acid decarboxylase (GAD65)
C. Rheumatoid factor
D. Anti-thyroid peroxidase
🟢 B. Anti-glutamic acid decarboxylase (GAD65)
🔴 Explanation: GAD65 autoantibodies are present in approximately 70–80% of patients with new-
onset type 1 diabetes and are the most sensitive marker.
Question 5
A patient with type 1 diabetes presents with fasting hyperglycemia despite adequate basal insulin.
Which phenomenon should be suspected?
A. Somogyi effect
B. Dawn phenomenon
C. Insulin resistance
D. Gastroparesis
🟢 B. Dawn phenomenon
🔴 Explanation: The dawn phenomenon is caused by nocturnal release of counterregulatory hormones
(growth hormone, cortisol) leading to early morning hyperglycemia despite adequate insulin.
Question 6
Which HbA1c target is generally recommended for most non-pregnant adults with diabetes?
,A. <6.0%
B. <6.5%
C. <7.0%
D. <8.0%
🟢 C. <7.0%
🔴 Explanation: The American Diabetes Association recommends an HbA1c target of <7.0% for most
non-pregnant adults to reduce microvascular complications.
Question 7
A 58-year-old patient with type 2 diabetes has an eGFR of 35 mL/min/1.73m². Which oral agent should
be avoided?
A. Sitagliptin
B. Metformin
C. Linagliptin
D. Empagliflozin
🟢 B. Metformin
🔴 Explanation: Metformin is contraindicated when eGFR is below 30 mL/min/1.73m² and should be
used with caution at eGFR 30–45 due to risk of lactic acidosis.
Question 8
Which class of antihyperglycemic agents works by inhibiting renal sodium-glucose cotransporter 2?
A. DPP-4 inhibitors
B. GLP-1 receptor agonists
C. SGLT2 inhibitors
D. Thiazolidinediones
🟢 C. SGLT2 inhibitors
🔴 Explanation: SGLT2 inhibitors block glucose reabsorption in the proximal renal tubule, promoting
glycosuria and lowering blood glucose independently of insulin.
Question 9
A patient on insulin reports hypoglycemia at 3:00 AM with rebound hyperglycemia at 7:00 AM. This is
most consistent with:
A. Dawn phenomenon
B. Somogyi effect
C. Insulin stacking
D. Gastroparesis
🟢 B. Somogyi effect
🔴 Explanation: The Somogyi effect involves nocturnal hypoglycemia triggering counterregulatory
hormone release, resulting in rebound morning hyperglycemia.
Question 10
Which of the following is the preferred initial injectable therapy for a patient with type 2 diabetes and
established cardiovascular disease?
A. NPH insulin
, B. GLP-1 receptor agonist
C. Premixed insulin
D. Regular insulin
🟢 B. GLP-1 receptor agonist
🔴 Explanation: GLP-1 receptor agonists with proven cardiovascular benefit are recommended as
preferred injectable therapy in patients with type 2 diabetes and atherosclerotic cardiovascular disease.
Question 11
A 62-year-old man with type 2 diabetes has an HbA1c of 9.2% on metformin monotherapy. What is
the most appropriate next step?
A. Add a sulfonylurea
B. Add a second oral agent or injectable therapy
C. Continue metformin alone
D. Discontinue metformin and start insulin
🟢 B. Add a second oral agent or injectable therapy
🔴 Explanation: When HbA1c is >1.5% above target on monotherapy, combination therapy with a
second agent is indicated.
Question 12
Which of the following is a common adverse effect of metformin?
A. Weight gain
B. Hypoglycemia
C. Gastrointestinal upset
D. Peripheral edema
🟢 C. Gastrointestinal upset
🔴 Explanation: Metformin commonly causes gastrointestinal side effects including diarrhea, nausea,
and abdominal discomfort.
Question 13
Diabetic ketoacidosis is characterized by all of the following EXCEPT:
A. Hyperglycemia
B. Metabolic acidosis
C. Ketosis
D. Respiratory alkalosis
🟢 D. Respiratory alkalosis
🔴 Explanation: DKA presents with metabolic acidosis, not respiratory alkalosis. Compensatory
respiratory alkalosis may occur but is not a defining feature.
Question 14
A patient with DKA has a pH of 7.12, bicarbonate of 8 mEq/L, and glucose of 480 mg/dL. What is the
initial priority?
A. Insulin bolus
B. IV fluid resuscitation with normal saline
